Latli B - Search Results

1

Mass balance and metabolite profiling of steady-state faldaprevir, a hepatitis C virus NS3/4 protease inhibitor, in healthy male subjects.

Chen LZ, Rose P, Mao Y, Yong CL, St George R, Huang F, Latli B, Mandarino D, Li Y. Chen LZ, et al. Among authors: latli b. Antimicrob Agents Chemother. 2014;58(4):2369-76. doi: 10.1128/AAC.02156-13. Epub 2014 Feb 10. Antimicrob Agents Chemother. 2014. PMID: 24514093 Free PMC article. Clinical Trial.

2

Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor.

Chen LZ, Sabo JP, Philip E, Rowland L, Mao Y, Latli B, Ramsden D, Mandarino DA, Sane RS. Chen LZ, et al. Among authors: latli b. Antimicrob Agents Chemother. 2015 Jan;59(1):25-37. doi: 10.1128/AAC.03861-14. Epub 2014 Oct 13. Antimicrob Agents Chemother. 2015. PMID: 25313217 Free PMC article. Clinical Trial.

3

Hepatitis C virus serine protease: synthesis of radioactive and stable isotope-labeled potent inhibitors.

Latli B, Hrapchak M, Gorys V, Llinàs-Brunet M, Campbell SS, Song J, Senanayake CH. Latli B, et al. J Labelled Comp Radiopharm. 2014 May 15;57(5):350-7. doi: 10.1002/jlcr.3187. Epub 2014 Feb 13. J Labelled Comp Radiopharm. 2014. PMID: 24700697

4

Synthesis of deleobuvir, a potent hepatitis C virus polymerase inhibitor, and its major metabolites labeled with carbon-13 and carbon-14.

Latli B, Hrapchak M, Chevliakov M, Li G, Campbell S, Busacca CA, Senanayake CH. Latli B, et al. J Labelled Comp Radiopharm. 2015 May 30;58(6):250-60. doi: 10.1002/jlcr.3294. Epub 2015 May 11. J Labelled Comp Radiopharm. 2015. PMID: 25964148

5

A Radioactivity-mass Spectrometry Calibration Method Coupled with Biosynthesis to Generate a Metabolite Standard for Enzyme Kinetics Studies.

Wang T, Thomas C, Latli B, Hrapchak M, Taub ME. Wang T, et al. Among authors: latli b. J Pharm Sci. 2024 Sep;113(9):2933-2939. doi: 10.1016/j.xphs.2024.07.019. Epub 2024 Jul 23. J Pharm Sci. 2024. PMID: 39053728

6

Synthesis of a potent cathepsin s inhibitor labeled with deuterium and carbon-14.

Latli B, Hrapchak M, Lorenz JC, Busacca CA, Senanayake C. Latli B, et al. Curr Radiopharm. 2012 Oct;5(4):314-7. doi: 10.2174/1874471011205040314. Curr Radiopharm. 2012. PMID: 22724423

7

Sodium-proton exchanger isoform-1: synthesis of a potent inhibitor labeled with deuterium and carbon-14.

Latli B, Haddad N, Hrapchak M, Wei X, Tang W, Song JJ, Senanayake CH. Latli B, et al. Curr Radiopharm. 2013 Mar;6(1):7-11. doi: 10.2174/1874471011306010002. Curr Radiopharm. 2013. PMID: 23256768

8

A potent IκB kinase-β inhibitor labeled with carbon-14 and deuterium.

Latli B, Eriksson M, Hrapchak M, Busacca CA, Senanayake CH. Latli B, et al. J Labelled Comp Radiopharm. 2016 Jun 30;59(8):300-4. doi: 10.1002/jlcr.3398. Epub 2016 Apr 13. J Labelled Comp Radiopharm. 2016. PMID: 27073120

9

Synthesis of empagliflozin, a novel and selective sodium-glucose co-transporter-2 inhibitor, labeled with carbon-14 and carbon-13.

Hrapchak M, Latli B, Wang XJ, Lee H, Campbell S, Song JJ, Senanayake CH. Hrapchak M, et al. Among authors: latli b. J Labelled Comp Radiopharm. 2014 Oct;57(12):687-94. doi: 10.1002/jlcr.3240. Epub 2014 Oct 21. J Labelled Comp Radiopharm. 2014. PMID: 25332189

10

A novel five-lipoxygenase activity protein inhibitor labeled with carbon-14 and deuterium.

Latli B, Hrapchak M, Gao JJ, Busacca CA, Senanayake CH. Latli B, et al. J Labelled Comp Radiopharm. 2015 Jul;58(9):390-4. doi: 10.1002/jlcr.3319. Epub 2015 Jul 20. J Labelled Comp Radiopharm. 2015. PMID: 26190342

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34 results

Search Page

Filters